A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

PHASE3CompletedINTERVENTIONAL
Enrollment

421

Participants

Timeline

Start Date

October 21, 2014

Primary Completion Date

June 4, 2015

Study Completion Date

April 26, 2016

Conditions
Forehead RhytidesGlabellar Rhytides
Interventions
BIOLOGICAL

OnabotulinumtoxinA

OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.

DRUG

Normal Saline

Placebo (normal saline) injected into the protocol-specified areas on Day 1.

Trial Locations (16)

33431

Steven Fagien, MD, PA, Boca Raton

35205

Total Skin and Beauty Dermatology Center, PC, Birmingham

46032

Laser & Skin Surgery Center of Indiana, Carmel

48322

Henry Ford Medical Center, West Bloomfield

70006

Coleman Center For Cosmetic Dermatologic Surgery, Metairie

80111

About Skin Dermatology and DermSurgery, PC, Greenwood Village

85308

Advanced Research Associates, Glendale

90404

Clinical Science Institute, Santa Monica

97210

NW Dermatology and Research Center, Portland

V5Z 4E1

Carruthers Dermatology Centre, Vancouver

Dr. Shannon Humphrey, Inc., Vancouver

Jean Carruthers Cosmetic Dermatology, Vancouver

M5R 3N8

Sweat Clinics of Canada, Toronto

H3Z 1B7

Arthur Swift Research, Inc., Westmount

Unknown

Aesthetic Surgery Ireland, Dublin

Beacon Face and Dermatology Clinic, Dublin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY